CN1570145A - Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method - Google Patents
Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method Download PDFInfo
- Publication number
- CN1570145A CN1570145A CN 200410018080 CN200410018080A CN1570145A CN 1570145 A CN1570145 A CN 1570145A CN 200410018080 CN200410018080 CN 200410018080 CN 200410018080 A CN200410018080 A CN 200410018080A CN 1570145 A CN1570145 A CN 1570145A
- Authority
- CN
- China
- Prior art keywords
- gonococcus
- gene
- probe
- chip
- pathogenic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 244000052769 pathogen Species 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 22
- 238000003745 diagnosis Methods 0.000 title claims description 18
- 206010061218 Inflammation Diseases 0.000 title claims description 16
- 230000004054 inflammatory process Effects 0.000 title claims description 16
- 206010059866 Drug resistance Diseases 0.000 title description 2
- 239000000523 sample Substances 0.000 claims abstract description 51
- 241000588653 Neisseria Species 0.000 claims abstract description 33
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 238000009396 hybridization Methods 0.000 claims abstract description 21
- 241000202921 Ureaplasma urealyticum Species 0.000 claims abstract description 14
- 241000606153 Chlamydia trachomatis Species 0.000 claims abstract description 13
- 229940038705 chlamydia trachomatis Drugs 0.000 claims abstract description 13
- 229960000268 spectinomycin Drugs 0.000 claims abstract description 12
- 238000013461 design Methods 0.000 claims abstract description 8
- 239000012634 fragment Substances 0.000 claims abstract description 8
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims abstract description 8
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000012544 monitoring process Methods 0.000 claims abstract description 6
- 230000003115 biocidal effect Effects 0.000 claims abstract description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims abstract description 3
- 239000002751 oligonucleotide probe Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 108700001094 Plant Genes Proteins 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000000869 mutational effect Effects 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 3
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 3
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003306 quinoline derived antiinfective agent Substances 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 101150010856 CRT gene Proteins 0.000 claims description 2
- 102000003844 DNA helicases Human genes 0.000 claims description 2
- 108090000133 DNA helicases Proteins 0.000 claims description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 150000007660 quinolones Chemical class 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 101150117115 V gene Proteins 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 101150015970 tetM gene Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 239000004098 Tetracycline Substances 0.000 abstract description 3
- 229960002180 tetracycline Drugs 0.000 abstract description 3
- 229930101283 tetracycline Natural products 0.000 abstract description 3
- 235000019364 tetracycline Nutrition 0.000 abstract description 3
- 150000003522 tetracyclines Chemical class 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000000143 urethritis Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 240000002877 Artemisia absinthium Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 108010018903 S-linalool synthase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A detection method for pathogen gonococcus, chlamydia trachomatis, and ureaplasma urealyticum in genitourinary tract and a preparation method for quinolone-resistant antibiotic, spectinomycin resistant, and tetracycline resistant integrated gene chip are disclosed. The gene chip comprises a detection system and a monitoring system. The detection system designs relative oligonucleotide probe according to the specific fragment sequence of three pathogens and mutable site of the medicine resistant gene, the probe fixed on the chip hybridizes with the amplified product of the specific sample, and the sort of the urethritis pathogen and the medicine resistant type can be detected according to the hybridization signal. The whole probes of the monitoring system and the detection system are in the same zone. The chip is characterized in that three venereal pathogens and their medicine resistance can be detected at the same time by the chip.
Description
Technical field
The present invention relates to detect the methods for making and using same of inflammation of genitourinary tracts pathogenic agent and chemical sproof integrated diagnosis gene chip thereof.
Background technology
Sexually transmitted disease (STD) be a class sickness rate high, to the great communicable disease of human health risk.In the clinical symptom of sexually transmitted disease (STD), modal clinical manifestation is an inflammation of genitourinary tracts, causes that the modal pathogenic agent of inflammation of genitourinary tracts is gonococcus, chlamydia trachomatis and Ureaplasma urealyticum.To gonococcal diagnosis, be mainly direct microscopy and cell cultures.Directly microscopy fast but accuracy is low, cell cultures accuracy height but gonococcus are cultivated and need 48 hours.The chlamydozoan cell cultures: susceptibility is 80%-90%, and the positive can be made a definite diagnosis, but above-mentioned technology is special, and is strict to operator and experimental installation, carries out still difficulty in general hospital and finish.Chlamydia trachomatis cytolgical examination method: in cells infected, can have chlamydial inclusion body to exist.Take cell specimen to make smear from infection site, Ji's nurse Sa dyeing inclusion body is blueness or mulberry, and iodine staining shows brown.But susceptibility poor (40%), less at present employing.The laboratory diagnosis of ureaplasma urealyticum infection mainly is the cultivation and the serological identification of mycoplasma, adopts culture method to need 48 hours and false positive rate height.All these inspection methods all have two big defectives, and the one, efficient is low, once can only detect a kind of pathogenic agent, and it is many that resistance is detected step, complicated operation, spended time is long.The 2nd, higher to acute inflammation of genitourinary tracts phase pathogen detection positive rate, and lower to chronic inflammation of genitourinary tracts phase pathogen detection positive rate.At present domestic conventional as yet clinically resistance of carrying out gonococcus and mycoplasma detects, and to the treatment of inflammation of genitourinary tracts mostly by rule of thumb, easily causes the state of an illness to incur loss through delay or patient's overspending.Discovered in recent years is in causing the pathogenic agent of inflammation of genitourinary tracts, and the ratio of independent a kind of pathogenic infection is less, and the large percentage of multiple pathogenic infection is arranged simultaneously.Therefore, be badly in need of a kind of quick, easy, standardized detection method accurately of development, can detect the pathogenic agent kind and the resistance type thereof of acute or chronic inflammation of genitourinary tracts once.The appearance of biochip technology is readily solved this difficult problem.The DNA chip technology obtains widespread use in genetic expression, detection in Gene Mutation, Study on gene polymorphism and gene diagnosis field.But have only part scientific research institution and high-tech company to grasp the DNA chip technology at present at home, yet there are no report about inflammation of genitourinary tracts pathogenic agent and chemical sproof integrated diagnosis gene chip thereof.
Summary of the invention
The object of the present invention is to provide a kind of three kinds of pathogenic agent that are used for inflammation of genitourinary tracts and to the integrated diagnosis gene chip and the application method thereof of three kinds of drug resistances, and have the monitoring system of detection and ensure the quality of products.Utilize this chip, both improved efficient, reduced cost again, the coincidence rate of diagnosis is brought up to more than 95% by integrated operation once.
Design of the present invention is as follows;
1. the fixing probe of gonococcus, chlamydia trachomatis and three kinds of pathogenic agent conserved sequences of Ureaplasma urealyticum simultaneously on chip, and to the multiple probe in quinolone antibiotic, spectinomycin and tetracycline resistance gene mutational site, only use patient's a urogenital tract secretory product cotton swab, only need a PCR and a hybridization, just can be in 5 hours promptly and accurately affirmation examinee whether suffer from above-mentioned three kinds of pathogenic agent and to three kinds of antibiotic resistances.
2. many medicals diagnosis on disease gene chip relates to multiple complicated physical process and biochemical reaction, as point sample, the preparation of dna profiling, processes such as polymerase chain reaction (PCR) amplification, mark, hybridization, washing, detection, and possible pollution in each step, the present invention has corresponding quality-guarantee and detects monitoring system on chip, adopt the method for negative control and positive control to guarantee detection accuracy, reduces error.
3. because multiple pathogen detection chip is a kind of polygenic reactive system, need us, the amplimer of the high recall rate that the design expanding fragment length is different by Computer Analysis and experiment screening.
4. applying unit is if any the fluorescent scanning instrument, and sample amplified production mark uses Cy5 or Cy3 fluorescent mark, can save experimental period.As not having the fluorescent scanning instrument, sample amplified production mark uses Dig digoxin colour developing mark, reduces experimental cost.
Technical scheme is as follows;
Integrated diagnosis chip of the present invention is at gonococcus, chlamydia trachomatis and three kinds of venereal disease pathogenic agent of Ureaplasma urealyticum with to quinolones, spectinomycin and three kinds of antibiotic drug resistant genes of tsiklomitsin.These pathogenic agent and drug resistant gene be the research of existing a large amount of molecular biology aspects at home and abroad, its characterizing gene sequence with diagnostic significance is announced, can use molecular biological gene isolation amplification technique to obtain: reference culture and the susceptibility Quality Control bacterial strain of getting gonococcus, chlamydia trachomatis and Ureaplasma urealyticum, extract DNA respectively as template, with reference to the gene order design primer of announcing, pcr amplification purpose fragment, be cloned on the plasmid then and increase in intestinal bacteria, it is standby to put forward plasmid DNA.
Said gene chip comprises two systems, and first part is a supervisory system, and second section is a detection system.Supervisory system is made of negative and positive each two crt gene probe, detection system designs corresponding oligonucleotide probe according to the special fragment sequence of gonococcus, chlamydia trachomatis and Ureaplasma urealyticum with to the drug-tolerant gene mutation site of quinolone antibiotic, spectinomycin and tsiklomitsin; All probes of Monitoring systems and detection system are positioned at the same area; The sample amplified production of mark under identical hybridization conditions simultaneously with all probe reactions of supervisory system and detection system.
Supervisory system comprises four parts, is respectively: 1. sampling liquid, be chip negative control (1), and if no signal is detected in the hybridization back, show normal; If hybridization signal is arranged, show that sampling liquid has pollution; 2. plant gene probe A, negative contrast (2) if no signal is detected in the hybridization back, shows normal; If hybridization signal is arranged, show that there is pollution in system; 1 or 2 one of them hybridization signal appears, this chip can not use; 3. plant gene probe B, positive contrast (1), this plant gene DNA joins before pcr amplification in the amplification system according to a certain percentage, to detect amplification efficiency.If it is normal that the detection of hybridization back has signal; If the amixia signal shows that the mark effect is undesirable.4. primer probe, positive contrast (2), signal is arranged is normal if the hybridization back is detected; If the amixia signal shows that crossover process or washing process have problem.
Said plant gene can be by to obtaining from the phantol synthase gene of artemisia (Artemisia annua) absinth (wormwood) ((3R)-linalool synthase (QH5)) clone, and this is a prior art.
Detection system with the mutational site probe stationary of the target gene probe of three kinds of pathogenic agent conserved regions and drug resistant gene on chip.If certain probe of hybridization back has signal, show and contain corresponding pathogenic agent in this sample or certain medicine resistance.Probe can adopt the ordinary method point sample on the slide of special processing.
The present invention has designed seven groups of amplimers at the high recall rate of target gene according to three kinds of venereal disease pathogenic agent and three kinds of antibiotic resistances of integrated diagnosis, and its sequence is as follows:
Gonococcus 5 '-GGATGATGAGTTGCTTTGTT-3 '
5’-TAATTGGCTCATGTTGTATCTC-3’
Chlamydia trachomatis 5 '-TGCGGTTGCGTGTCCTGTGA
5’-GATCGCCCAGACAATGCTCCA
Ureaplasma urealyticum 5 '-GCGACGCTTTTGGATG-3 '
5’-GCCTGCGCTCGTTTTAC-3’
Gonococcus DNA helicase 5 '-ATCCGCCACGACCACAAAT-3 '
5’-CGTCCACCGATCCGAAGTT-3’
Gonococcus topoisomerase I V 5 '-GCACGCTTCCCATACCGA-3 '
5’-TCCACCGTCCCCTGATTG-3’
The anti-spectinomycin 5 ' of gonococcus-TCGTCAGCTCGTGTTGTG-3 '
5’-ATTACTAGCGATTCCGACTTC-3’
The anti-tsiklomitsin 5 ' of gonococcus and mycoplasma-GTGTGTGACGAACTTTACCGA-3 '
5’-GGACCTCGATGTGTTGATGA-3’
Above-mentioned primer can adopt the dna synthesizer synthetic and through HPLC (high performance liquid chromatography) (HPLC) purifying, this method is a kind of existing technology, and the present invention repeats no more.Accompanying drawing is seen in the gene chip explanation.
With above-mentioned disclosed primer amplification and label probe, the sample amplified production of mark under identical hybridization conditions simultaneously with all probe reactions of supervisory system and detection system, according to results of hybridization, can diagnose inflammation of genitourinary tracts pathogenic agent and resistance type thereof.
Description of drawings
Fig. 1 chip synoptic diagram (fluorescent method)
Among the figure 1. negative controls, 1 2. gonococcus to responsive 3. positive controls, 1 4. gonococcus of quinolone 5. chlamydozoans 6. mycoplasmas 7. gonococcus to responsive 8. gonococcus of spectinomycin to spectinomycin resistance 9. positive controls 210. gonococcus to low resistance 11. gonococcus of quinolone to responsive 12. gonococcus of quinolone to quinolone height resistance 13. gonococcus and mycoplasma to tetracycline resistant 14. negative controls 2
Embodiment
Below will relevant details of the present invention be further elaborated, but embodiment does not limit protection scope of the present invention by embodiment.
Embodiment 1
The processing of sample and mark
Get cotton swab from patient's urogenital tract, add the 100ul lysate, 50 ℃, 30min, boiling water bath is 10 minutes again.Get supernatant as template DNA.
Get the DNA sample 5ul for preparing and mix with the 20ulPCR amplification system that (amplification system comprises the 2.5ulPCR reaction buffer, 5nmol dNTPs, the upstream of each 10pmol and downstream primer, 1.25UpfuDNA polysaccharase) prepare the DNA sample purpose fragment of mark by following thermal cycling process, at first 94 ℃, 5min, again with 94 ℃, 50S, 52 ℃, 50S, 72 ℃, 1min circulation 35 times, is extended 5min by last 72 ℃.Fluorescent mark adopts the Cy5 labeled primer, and the colour developing mark adopts the Dig labeled primer.
Embodiment 2
Chip manufacture method
The probe that dilution is good mixes with 2 * Spoting Solution equal-volume, making final concentration is 40pmols/ μ l, by Cartesian Tech., PROSYS5510A chip manufacturing system dot matrix is in aldehyde group modified slide surface, places under 75% relative humidity, the 30 ℃ of conditions to fix in 48-72 hour.With chip boiling water bath 30 seconds, take out the room temperature thorough drying then.
Embodiment 3
Fluorescent method hybridization detects
Get fluorescently-labeled target DNA fragment 5ul, 99 ℃ of sex change 5min are then with 20ul hybridization solution mixing, get 10ul and drip in the chip surface of stationary probe, covered places 40 ℃ of wet boxes to hybridize 30min, in washing lotion I, swing then and wash 10min, swing among the washing lotion II and wash 1min, airing.At last with Scanarray3000 scanning of General Scanning chip signal analytical system and analytical results.(Cy5 is to photaesthesia, the lucifuge of trying one's best during operation.)
Embodiment 4
Development process hybridization detects
1. the target DNA fragment 5ul of mark, 99 ℃ of sex change 5min then with 20ul hybridization solution mixing, get 10ul and drip in the chip surface of stationary probe, and covered places 40 ℃ of wet boxes to hybridize 30min.
2. take out chip from wet box, remove cover glass, drop into rapidly in the reagent 6, shaking table swings and washes 10min (60-100 time/min) under the room temperature (25 ℃).Then chip is put into reagent 7, take out chip behind the 1min, absorb point sample district unnecessary liquid in addition with thieving paper.
3. get 0.2ml eppendorf pipe, add the reagent 9 of reagent 8, the 1 μ l of 25 μ l successively, fully behind the mixing, drip in the point sample district of chip, covered leaves standstill 30min.
4. the removal cover glass is absorbed unnecessary liquid, puts into reagent 7 and swings and wash 30s, takes out chip, absorbs unnecessary liquid.
5. 10 of reagent drawing 50 μ l leave standstill 1min in the point sample district of chip, absorb unnecessary liquid.
6. get a slice film and put into reagent 11, after soaking 10s, then film is taken out, carefully with nylon membrane one angular contact on thieving paper, be adsorbed in the unnecessary reagent on nylon membrane surface with absorption, and carefully be covered in the point sample district (noticing that nylon membrane can not move) of chip, be inverted in rapidly in the wet box, compacting gently (noticing that chip can not move), lucifuge leaves standstill 30min.
7. the taking-up chip is carefully uncovered film, and distilled water swings gently to be washed several seconds, and it is dried naturally, observe visible hybridization signal with magnifying glass and be the mulberry round dot, or observe at computer screen after the ordinary optical scanner scanning, and the result is analyzed with corresponding software.
Claims (6)
1. an inflammation of genitourinary tracts pathogenic agent and drug-fast integrated diagnosis gene chip thereof, it is characterized in that, this integrator gene chip is made of supervisory system and detection system, supervisory system is made of negative and positive each two crt gene probe, detection system designs corresponding oligonucleotide probe according to the special fragment sequence of gonococcus, chlamydia trachomatis and Ureaplasma urealyticum with to the drug-tolerant gene mutation site of quinolone antibiotic, spectinomycin and tsiklomitsin; All probes of Monitoring systems and detection system are positioned at the same area; The sample amplified production of mark under identical hybridization conditions simultaneously with all probe reactions of supervisory system and detection system.
2. by described inflammation of genitourinary tracts pathogenic agent of claim 1 and drug-fast integrated diagnosis gene chip thereof, it is characterized in that, supervisory system comprises four parts, be respectively: (1) chip negative control sampling liquid, (2) negative control is plant gene probe A, (3) positive control is plant gene probe B, (4) chip positive control primer probe; Detection system comprises conserved regions sequence probe and three kinds of resistance determining area sequence probes of three kinds of venereal disease pathogen nucleic acids; Be respectively: (1) is according to gonococcus cryptic plasmid sequences Design probe in detecting gonococcus, (2) detect chlamydozoan according to chlamydia trachomatis plasmid sequence designing probe, (3) detect mycoplasma according to Ureaplasma urealyticum 16sRNA designing probe, (4) detect the low resistance of quinolone according to gonococcus helicase gene order mutational site designing probe, (5) detect quinolone height resistance according to gonococcus topoisomerase I V gene order mutational site designing probe, (6) detect the resistance of anti-spectinomycin according to gonococcus 16srRNA gene order mutational site designing probe, (7) detect resistance to tsiklomitsin according to the common tetM gene order designing probe of gonococcus and Ureaplasma urealyticum.
3. by described inflammation of genitourinary tracts pathogenic agent of claim 1 and drug-fast integrated diagnosis gene chip thereof, it is characterized in that, gene information according to gonococcus, chlamydia trachomatis and Ureaplasma urealyticum and anti-quinolone, anti-spectinomycin and anti-tsiklomitsin, design seven groups of amplimers at the high recall rate of target gene, they are respectively:
Gonococcus 5 '-GGATGATGAGTTGCTTTGTT-3 '
5’-TAATTGGCTCATGTTGTATCTC-3’
Chlamydia trachomatis 5 '-TGCGGTTGCGTGTCCTGTGA
5’-GATCGCCCAGACAATGCTCCA
Ureaplasma urealyticum 5 '-GCGACGCTTTTGGATG-3 '
5’-GCCTGCGCTCGTTTTAC-3’
Gonococcus DNA helicase 5 '-ATCCGCCACGACCACAAAT-3 '
5’-CGTCCACCGATCCGAAGTT-3’
Gonococcus topoisomerase I V 5 '-GCACGCTTCCCATACCGA-3 '
5’-TCCACCGTCCCCTGATTG-3’
The anti-spectinomycin 5 ' of gonococcus-TCGTCAGCTCGTGTTGTG-3 '
5’-ATTACTAGCGATTCCGACTTC-3’
The anti-tsiklomitsin 5 ' of gonococcus and mycoplasma-GTGTGTGACGAACTTTACCGA-3 '
5’-GGACCTCGATGTGTTGATGA-3’
4. the application method of inflammation of genitourinary tracts pathogenic agent as claimed in claim 1 and drug-fast integrated diagnosis gene chip thereof, it is characterized in that, detect gonococcus, chlamydia trachomatis and three kinds of venereal disease pathogenic agent of Ureaplasma urealyticum simultaneously and quinolones, spectinomycin and three kinds of antibiotic resistances of tsiklomitsin.
5. the application method of inflammation of genitourinary tracts pathogenic agent as claimed in claim 4 and drug-fast integrated diagnosis gene chip thereof is characterized in that, in whole testing process, only needs a PCR, a hybridization.
6. as the application method of claim 4 or 5 described inflammation of genitourinary tracts pathogenic agent and drug-fast integrated diagnosis gene chip thereof, it is characterized in that the sample amplified production is labeled as fluorescein Cy5 or Cy3 fluorescent mark, or be digoxin colour developing mark.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410018080 CN1261594C (en) | 2004-04-29 | 2004-04-29 | Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410018080 CN1261594C (en) | 2004-04-29 | 2004-04-29 | Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1570145A true CN1570145A (en) | 2005-01-26 |
CN1261594C CN1261594C (en) | 2006-06-28 |
Family
ID=34479341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410018080 Expired - Fee Related CN1261594C (en) | 2004-04-29 | 2004-04-29 | Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1261594C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092645B (en) * | 2005-06-24 | 2011-05-11 | 亚洲基因科技股份有限公司 | Novel method for diagnosing pathogens of sexually transmitted diseases |
CN104513854A (en) * | 2014-10-29 | 2015-04-15 | 常州百代生物科技有限公司 | Pathogen nucleic acid-drug resistant gene detection kit and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010127498A1 (en) * | 2009-05-08 | 2010-11-11 | Gui Yaoting | Device and method detecting the inflammation of urinogenital system by pathgen information |
-
2004
- 2004-04-29 CN CN 200410018080 patent/CN1261594C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092645B (en) * | 2005-06-24 | 2011-05-11 | 亚洲基因科技股份有限公司 | Novel method for diagnosing pathogens of sexually transmitted diseases |
CN104513854A (en) * | 2014-10-29 | 2015-04-15 | 常州百代生物科技有限公司 | Pathogen nucleic acid-drug resistant gene detection kit and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1261594C (en) | 2006-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111197112A (en) | Primer, probe and kit for detecting novel coronavirus | |
CN101541979B (en) | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system | |
CN107099618A (en) | A kind of LAMP primer composition thing and its related application for being used to detect urogenital tract pathogenic microorganisms | |
CN107488748B (en) | Composition for detecting 23 respiratory pathogens, kit and detection method thereof | |
CN102002531A (en) | Toxoplasma gondii detection kit and application thereof | |
CN108690881A (en) | Measuring method for diagnosing dermatophytosis | |
CN111500778A (en) | Method for detecting 2019 novel coronavirus by combining reverse transcription loop-mediated isothermal amplification with gold nano biosensing | |
CN113846191B (en) | Primer and probe for detecting novel coronavirus and application of primer and probe | |
CN1814797B (en) | Method for identifying 28 frequent phathogenic bacteria for clinical bacteremia | |
CN105349664A (en) | Gene chip and kit for detecting pathogenic bacteria in cerebrospinal fluid of central nervous system bacterial infester | |
CN1261594C (en) | Genitourinary tract inflammation pathogenic organism and drug resistance integrated diagnosis gene chip and method | |
CN102424862B (en) | Genotyping chip for legionella pneumophila, and kit for detection of legionella pneumophila | |
CN101497926A (en) | Reagent kit for rapidly and synchronously detecting Chlamydi trachomatis, Urealpasma parvum and Ureaplasma urealyticum | |
CN1188529C (en) | Nano gold mark silver dyeing detection method of gene chip | |
CN110643740A (en) | Real-time fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) detection primer, probe and detection kit for Palimam serogroup virus | |
CN1414112A (en) | Gene chip used for identifying pathogenic bacteria in blood and its making method | |
CN113564271B (en) | Primer probe set for pathogenic bacterium typing quantitative detection, kit and sample purification method | |
CN105331718A (en) | Gene chip and kit for detecting pathogenic bacteria in cerebrospinal fluid of patient with fungal infection of central nervous system | |
WO2021039777A1 (en) | Method for examining rheumatoid arthritis | |
CN112080556B (en) | Method for performing multiple rapid sequencing on gonococcus drug-resistant gene | |
CN104805210B (en) | Gene detection method of Leber's hereditary optic neuropathy, (LHON) gene chip and kit | |
JP2003144153A (en) | Method for detecting gene, primer for detecting gene, dna microarray and kit for detecting gene | |
CN102676690B (en) | Reagent kit, method, primers and probe for quantitative detection of nucleic acid of swine fever virus | |
CN2771862Y (en) | rRNA membrane chip for detecting blood cerebrospinal fluid nosetiology | |
CN1261590C (en) | Process for testing gene chip used to detect bacteremia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060628 Termination date: 20180429 |
|
CF01 | Termination of patent right due to non-payment of annual fee |